-
AMAG Announces Preliminary Results - Analyst Blog
Wednesday, January 12, 2011 - 10:01am | 619AMAG Pharmaceuticals (AMAG) recently discussed its preliminary fourth quarter results and provided guidance for 2011. AMAG also discussed its plans for expanding commercialization of Feraheme. Feraheme is an intravenous (IV) therapy for the treatment of iron deficiency anemia (IDA) in patients...
-
FDA Awards SDIX Method Equivalency for Salmonella Enteritidis Detection
Wednesday, January 12, 2011 - 9:45am | 88SDIX™ (NASDAQ: SDIX) today announced that its RapidChek SELECT Salmonella Enteritidis test system has been reviewed by the U.S. Food and Drug Administration and determined to be equivalent in accuracy, precision and sensitivity to their current standard methods for poultry house environmental drag...
-
Benzinga's Top Pre-Market NASDAQ Losers (ILMN, SNDK, VOD, RYAAY)
Wednesday, January 12, 2011 - 9:43am | 111Illumina Inc (NASDAQ: ILMN) dipped 1.99% to $66 in the pre-market session. ILMN has purchased Epicentre Biotechnologies. SanDisk Corporation (NASDAQ: SNDK) fell 1.65% to $51.34 in the pre-market session. SNDK's trailing-twelve-month ROA is 13.34%. Vodafone Group Plc (NASDAQ: VOD) moved down 1.39%...
-
AMAG Announces Preliminary Results - Analyst Blog
Wednesday, January 12, 2011 - 9:15am | 619AMAG Pharmaceuticals (AMAG) recently discussed its preliminary fourth quarter results and provided guidance for 2011. AMAG also discussed its plans for expanding commercialization of Feraheme. Feraheme is an intravenous (IV) therapy for the treatment of iron deficiency anemia (IDA) in patients...
-
Piper Jaffray Overweight On Illumina, Inc. (ILMN)
Wednesday, January 12, 2011 - 8:35am | 156Piper Jaffray has an Overweight rating on shares of Illumina, Inc. (NASDAQ: ILMN). It is reviewing its price target of $61. In the note sent to clients, Piper Jaffray writes, "Illumina pre-announced favorable 4Q10 top-line results, with revenue anticipated to increase ~44% to ~$260M, ahead of...
-
TMO Deal Opens Up Asia - Analyst Blog
Tuesday, January 11, 2011 - 8:01pm | 536Thermo Fisher Scientific (TMO) has managed to get clearance for its proposed acquisition of Dionex Corporation (DNEX) while passing smoothly through the scanning of HSR Act. The company is in the process of receiving other clearances and expects to complete the acquisition in the first quarter of...
-
TMO Deal Opens Up Asia - Analyst Blog
Tuesday, January 11, 2011 - 7:40pm | 536Thermo Fisher Scientific (TMO) has managed to get clearance for its proposed acquisition of Dionex Corporation (DNEX) while passing smoothly through the scanning of HSR Act. The company is in the process of receiving other clearances and expects to complete the acquisition in the first quarter of...
-
AMAG Pharmaceuticals Rises 8.8% On Upgrade News (AMAG)
Tuesday, January 11, 2011 - 4:45pm | 141Shares of AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) are currently up 8.8% at $18.16 per share during Tuesday afternoon trading. The company's share price got a boost when Madison Williams raised it rating for the stock from Accumulate to Buy. Today's trading range for shares of AMAG Pharmaceuticals...
-
Market Roundup (AMAG, ALTH, TIF, SVU, AMR, TAM, GOL, LFL)
Tuesday, January 11, 2011 - 1:17pm | 351Shares of AMAG Pharmaceuticals Inc (NASDAQ: AMAG) gained about 6%, as the drug sector's two key indexes were trading mixed. AMAG shares gained after analysts at Madison Williams upgraded the stock from “accumulate” to “buy.” However, shares of Allos Therapeutics Inc (NASDAQ: ALTH) dropped about 2%...
-
Pharmaceutical Product Development Announces Joint Venture Called BioDuro Biologics
Tuesday, January 11, 2011 - 10:24am | 254Goldman Sachs has published a research report on Pharmaceutical Product Development (NASDAQ: PPDI) after the company committed $25 million dollars to a joint venture with Taijitu Biologics Limited called BioDuro Biologics. In the report, Goldman Sachs writes "After the close, PPD announced that it...
-
Jefferies Maintains UW Rating On AMAG
Tuesday, January 11, 2011 - 9:21am | 65Jefferies is maintaining its rating on AMAG Pharmaceuticals (NASDAQ: AMAG). “We view below-consensus 2011 Feraheme sales guidance as too optimistic and maintain our below-guidance sales estimate,” Jefferies writes. “We remain bearish on Feraheme potential and keep our peak annual sales potential at...
-
15 Low Priced Stocks to watch on the move (CRDC),(FXEN),(RDNT),MOSY) more below
Monday, January 10, 2011 - 6:41pm | 16315 LOW PRICED STOCKS ON THE MOVE,On the move (CRDC),(FXEN),(RDNT),MOSY),(PRWP),(LYSCF),(PSTI),(VSCP),(IMRS),(CERS),(OCZ),(VUTV),(CRME),(INAP),(CHTP)all look good Technically...BIG WINNERS FROM OUR LOW PRICED PICKS LAST NIGHT AND EARLY TODAY INCLUDE (SOL),(ZAGG),(ASTM),(GU)and (EEE) up 25% from...
-
PPD Establishes Joint Venture with Taijitu Biologics for Drug Discovery of Large Molecules
Monday, January 10, 2011 - 5:51pm | 56PPD, Inc. (Nasdaq: PPDI) today announced it has established a joint venture with Taijitu Biologics Limited in the area of the discovery of novel biotherapeutics. The joint venture, named BioDuro Biologics, expands PPD's capability to deliver unique, highly differentiated drug discovery services for...
-
Bruker Corp Up 6.6% After Rating Upgrade (BRKR)
Monday, January 10, 2011 - 4:06pm | 118Shares of Bruker Corporation (Nasdaq: BRKR) are trading up 6.6% at $17.06 per share during the Monday afternoon trading session. The company was upgraded by UBS from a rating of Neutral to a rating of Buy. The day's trading range for shares of Bruker Corporation has been between $16.55 and $17.17...
-
Endo Pharma Receives CRL - Analyst Blog
Monday, January 10, 2011 - 1:31pm | 385Endo Pharmaceuticals' (ENDP) pipeline received a setback when the US Food and Drug Administration (FDA) issued a complete response letter (CRL) to the company regarding the new formulation of Opana ER. The painkiller is designed to resist attempts of crushing, breaking, pulverizing or making a...